Marberger M J, Andersen J T, Nickel J C, Malice M P, Gabriel M, Pappas F, Meehan A, Stoner E, Waldstreicher J
Department of Urology, University of Vienna, Austria.
Eur Urol. 2000 Nov;38(5):563-8. doi: 10.1159/000020356.
We evaluated prostate volume and prostate-specific antigen (PSA) as predictors of acute urinary retention (AUR) in men with benign prostatic enlargement (BPE).
Data were pooled from 3 identical 2-year, multinational, multicenter, non-US, placebo-controlled finasteride trials in 4,222 men with BPE and no evidence of prostate cancer.
The 2-year incidence of spontaneous AUR was higher in placebo patients with enlarged prostates (4.2% in men with prostate volume > or =40 ml vs. 1.6% in the <40 ml group) and higher PSA levels (3.9% in men with PSA > or =1.4 ng/ml vs. 0.5% in the <1.4 ng/ml group) at baseline. Finasteride reduced AUR incidence by 61% in men with larger prostates, by 63% in men with higher PSA levels, and by 47% in men with smaller prostates, compared with placebo.
BPE patients with larger prostate volumes, higher PSA levels and no evidence of prostate cancer have an increased risk of developing AUR and therefore derive the greatest benefit from the risk reduction seen with finasteride therapy.
我们评估了前列腺体积和前列腺特异性抗原（PSA）作为良性前列腺增生（BPE）男性急性尿潴留（AUR）预测指标的情况。
数据来自3项相同的为期2年的跨国、多中心、非美国的安慰剂对照非那雄胺试验，共纳入4222例BPE男性且无前列腺癌证据。
基线时，安慰剂组中前列腺增大患者的2年自发性AUR发生率更高（前列腺体积≥40 ml的男性为4.2%，而<40 ml组为1.6%），且PSA水平更高（PSA≥1.4 ng/ml的男性为3.9%，而<1.4 ng/ml组为0.5%）。与安慰剂相比，非那雄胺使前列腺较大的男性AUR发生率降低61%，PSA水平较高的男性降低63%，前列腺较小的男性降低47%。
前列腺体积较大、PSA水平较高且无前列腺癌证据的BPE患者发生AUR的风险增加，因此从非那雄胺治疗带来的风险降低中获益最大。
